ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.
Help employers find you! Check out all the jobs and post your resume.
